Biotech is quietly stepping into a leadership role here in early 2026 — and the move is not happening in a vacuum.After years of underperformance from 2021 through much of 2024, the sector began a powerful rebound in the second half of 2025.  That rally was significant. From its April 2025 lows, the SPDR S&P Biotech ETF (NASDAQ: IBB) surged roughly 75%, dramatically outperforming the broader market’s move over the same period.In many ways, that outperformance looked like a long-overdue catch-up trade.  ...

Iovance Biotherapeutics (NASDAQ:IOVA) shares are surging on Tuesday following the announcement of positive early data from a pilot clinical trial for its TIL cell therapy in advanced soft-tissue sarcomas.This news has energized investors as the broader market is experiencing gains, with the Nasdaq up 0.51%.Among the first six evaluable patients treated with lifileucel monotherapy, the trial showed a 50% confirmed objective response rate (ORR).The trial, conducted by Memorial Sloan Kettering Cancer Center, f ...

Grail (NASDAQ: GRAL) stock rose by more than 16% by midday. The move follows a couple of days of brutal declines after the release of top-line results from its three-year, 142,000-person trial of its Galleri multi-cancer early detection (MCED) test with England's National Health Service. What went wrong for Grail I discussed the stock's decline on the first day of trading after the release, and the market punished it again on Monday. However, let's focus on why the market may be optimistic about future dev ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma, and healthcare industries and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston B ...

江苏康为世纪生物科技股份有限公司 证券代码：688426 证券简称：康为世纪 公告编号：2026-009 公司董事会对杨凌先生在公司首次公开发行股票并上市项目持续督导期间做出的贡献表示衷心感谢！ 特此公告。 江苏康为世纪生物科技股份有限公司 董事会 2026年2月25日 王伟，男，硕士学历，现任中信证券投资银行管理委员会高级副总裁，保荐代表人。曾负责或参与的主 要项目有：瑞立科密主板 IPO、康为世纪科创板IPO、苏文电能创业板 IPO、华脉科技主板 IPO、苏文 电能非公开发行、维尔利可转债、索普集团可交债、悦达投资现金收购等项目。 关于更换持续督导保荐代表人的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 近日，江苏康为世纪生物科技股份有限公司（以下简称"康为世纪"或"公司"）收到中信证券股份有限公 司（以下简称"中信证券"）出具的《关于更换持续督导保荐代表人的函》，具体情况如下： 中信证券作为公司首次公开发行股票并在上海证券交易所科创板上市项目（以下简称"首次公开发行股 票并上市项目"）的保荐机构，原委派保荐代表 ...

Gosebruch provided an update on Galapagos’s legacy R&D asset, the TYK2 inhibitor GLPG3667. He noted that the company announced top-line Phase 2 results in December for studies in dermatomyositis and systemic lupus erythematosus (SLE). According to management, GLPG3667 met the primary endpoint in dermatomyositis, showing a statistically significant clinical benefit and improvements on secondary measures versus placebo.Gosebruch said Galapagos is “aggressively evaluating opportunities” across its focus areas ...

This Small-Cap Biotech Stock Is Soaring 29%. There's Excitement Over Its Prostate Cancer Drug. - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer DrugBy [Macken ...

分组1 - Myriad Genetics, Inc. reported a strong earnings beat for Q4 2025, with Non-GAAP EPS at $0.04, surpassing consensus estimates [1] - The stock price increased approximately 25% in pre-market trading following the earnings announcement [1] 分组2 - The article emphasizes the importance of combining scientific expertise with financial analysis in the biotech sector [1] - The focus is on identifying innovative biotechnology companies that are developing unique therapies and technologies [1] - The analysis aims to evaluate the science behind drug candidates, competitive landscape, clinical trial design, and market opportunities while considering financial fundamentals [1]

Key Takeaways MEDX touched a new 52-week high, rising 49.9% from its $23.46 low.The ETF targets patented first-line pharma and biologics, charging 85 bps in fees.A 28.43 weighted alpha signals potential for further near-term gains.For investors seeking momentum, the Horizon Kinetics Medical ETF (MEDX) is probably on the radar now. The fund just hit a 52-week high and is up 49.9% from its 52-week low price of $23.46 per share.  But are there more gains in store for this ETF? Let’s take a quick look at the fu ...

February 13, 2026 02:50 AM GMT 亚洲经济研究 | Asia Pacific Morgan Stanley Asia Limited Chetan Ahya 亚洲首席经济学家 Chetan.Ahya@morganstanley.com +852 2239-7812 Morgan Stanley Asia (Singapore) Pte. 甘永康 亚洲经济学家 Derrick.Kam@morganstanley.com +65 6834-8272 Morgan Stanley Asia Limited M Idea 观点：市场反馈与我们的共识 和分歧 投资者整体对亚洲持积极看法，但关注点主要集中在科技板 块；而我们认为复苏正在向非科技板块扩散。这意味着，在 相对配置层面，投资者更看好北亚（不含中国）。投资者在 微观层面对中国保持乐观，但同时也认可宏观层面所面临的 挑战。 要点 在本报告中，我们就以下与投资者反复讨论的关键议题，分享我们的看法： This translated report is made available for convenience only and is ba ...